A Study to Investigate Why Overweight People Regain Weight After Losing Weight in a Behavioral Weight Loss Program
Recruiting · NCT05748158 · Interventional (participants receive a specific treatment)
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
The goal of this clinical trial is to determine the physiological basis for the differences in weight regain among adults (25-59 years old) with obesity following participation in a behavioral weight loss program. Eligible participants will undergo a baseline evaluation after which they will enter an up to 20 week behavioral weight loss program with the goal of losing at least 7 percent of their baseline weight within 35 weeks. Participants who meet the weight loss goal will be asked to remain weight stable for 2 weeks after which they will undergo a clinical examination. They will then be observed for 1 year during which they will undergo 2 additional clinical examinations, one 4 months after completing the weight loss program, and the other 12 months after completing the weight loss program.
Who can take part
Inclusion criteria
- Age: 25 - \<60 years
- BMI: 30 - \<40 kg/m2 at the first screening visit
- Within 5% of current weight, for the past 6 months at the first screening visit
- Able to participate in ergometry testing
- Has a smart phone, tablet or computer with access to the internet
Exclusion criteria
- If 25-29 years old, \> 5% deviation from maximum weight (excluding weights while pregnant) since age 25 years
- If at least 30 years old, \> 5% deviation from maximum weight (excluding weights while pregnant) in last 5 years or ≥ 10% deviation from maximum weight (excluding weights while pregnant) since age 30 years
- History of pulmonary embolus in the past 6 months
- Cardiovascular disease (e.g. myocardial infarction, stroke, hospitalization for unstable angina, or transient ischemic attack) within the past 6 months
- Current major depressive disorder or history of major depressive disorder within 2 years
- Any regular tobacco or nicotine use in the past year
- Currently engaging in intense physical training or training for a sports event including, but not limited to, a marathon or body building
- Currently pregnant, or less than one-year post-partum or actively planning to become pregnant within the next two years
- Presently classified as being in New York Heart Association Class II or greater or dysrhythmia
- Diabetes (type 1 or 2 - HbA1c ≥ 6.5%, fasting glucose ≥ 126 mg/dL) or currently taking a glucose lowering medication
- Thyroid disease requiring hormones or medication or TSH \< 0.5 or \> 5 mIU/L
- Renal disease requiring dialysis
- Known HIV infection
- ALT or AST greater than 5 times the upper limit of normal or active gall bladder disease
- Significant anemia (Hgb \< 10 g/dL) or thrombocytopenia (platelet count \< 60,000 /mm3)
- Leukopenia defined as:
- Males: WBC \< 3,100 /mm3 or (WBC 3,100 - \< 4,000 /mm3 and at least 1 Duffy antigen (A, B) positive or no result) Females: WBC \< 3,400 /mm3 or (WBC 3,400 - \< 4,000 /mm3 and at least 1 Duffy antigen (A, B) positive or no result)
- Active cancer or current chemotherapy treatment, or history of cancer requiring treatment in the past 5 years except for non-melanoma skin cancers or cancers that have clearly been cured
- Current or past history of anorexia nervosa or bulimia nervosa
- Current or past diagnosis of binge eating disorder
- Diagnosis of other severe psychiatric disorder (e.g. schizophrenia, bipolar disorder)
- Unwillingness to abstain from marijuana/cannabis use for 3 weeks at each of the four assessment time points
- Known or suspected abuse or misuse of alcohol, prescription drugs, or recreational drugs
- Antiretroviral therapy (ART), including treatment for HIV, pre-exposure prophylaxis (PrEP) or post-exposure prophylaxis (PEP) within the past 3 months
- Regularly taking medication or supplement known to affect appetite, energy expenditure, or weight (e.g. appetite suppressants, steroids-including inhaled steroids but not topical, alpha-blockers, beta-blockers, certain psychotropic medications)
- Currently taking anticoagulant medication
- Currently enrolled in a supervised weight reduction program
- Prior or planned bariatric surgery, endoscopic therapy, device-based therapy for obesity, liposuction, cryolipolysis, or abdominoplasty
- Severely restricted diets: Vegan (no meat, fish, dairy, eggs, or honey), very low carbohydrate (\<15% calorie as carbohydrate), very low fat (\<15% calories as fat), or strictly gluten free
- Current celiac or diagnosed gluten intolerance or inflammatory bowel disease requiring specialized diet
- Night or rotating shift worker
- Known severe allergy (e.g. anaphylaxis) to nuts or other foods
- Systolic blood pressure (BP) \<90 mmHg and/or diastolic BP \<60 mmHg on 2 measurements during the clinical screening visit.
- Systolic blood pressure (BP) \>160 mmHg and/or diastolic BP \>100 mmHg on at least 2 measurements during the clinical screening visit or resting heart rate \< 45 beats per minute or \>100 on 2 measurements during the clinical screening visit.
- Metal implants, piercings that cannot be removed, or metal-based tattoos or hair treatments
- Exceeds limitations to fit dual-energy X-ray absorptiometry (DXA) field of view
- Known allergy to lidocaine or acetaminophen
- Non-compliance with appointments or tasks (food diaries, etc.) during the screening phase
- Blood clotting disorder or INR \> ULN or PT \> ULN or (a)PTT \> ULN
- Tendency to form thick or raised scars
- Inability to achieve weight stability (defined in section 4.2.1) during the 2 weeks prior to initiation of the baseline Doubly Labeled Water (DLW) assessment
- At high risk for suicide, as assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS)
Where it is running
3 locations listed across 2 US states.
- Columbia University Irving Medical Center - New York, New York, United States
- Drexel University - Philadelphia, Pennsylvania, United States
- University of Pennsylvania - Philadelphia, Pennsylvania, United States